PMC4444132_01
Computed tomography brain scans from a patient with triple-negative BC treated with eribulin (Case E1): (A) baseline, (B) after cycle 2 (resolution of brain lesion), (C) after cycle 4 (brain lesion remains resolved), and (D) after cycle 6 (relapse of brain lesion). Arrows indicate area with brain lesion.
bcbcr-9-2015-019f1.jpg
PMC4444132_01_bcbcr-9-2015-019f1.jpg
f1-bcbcr-9-2015-019
At study baseline, she had brain metastases in the left parietal cortex on computed tomography (CT) scan (Fig. 1A), for which she had previously received radiation therapy with a partial response (PR) about one month before initiation of eribulin. After cycle 2, there was complete resolution of the brain lesion (Fig. 1B) and a 45% reduction from baseline in the sum of the longest diameter of all target lesions. This response in the brain lesion was maintained at cycle 4, when it remained completely resolved on imaging (Fig. 1C). Disease progressed after cycle 6, with relapse of the brain lesion (Fig. 1D), and a 125% increase in all RECIST-evaluated lesions compared with the previous smallest value and a 24% increase with baseline.
PMC4444132_02
PMC4444132_03
PMC4444132_04
PMC4444132_05
PMC4444132_06